Impact of Mavacamten in the treatment of hypertrophic cardiomyopathy
DOI:
https://doi.org/10.63688/rx5qcw72Keywords:
Mavacamten, hypertrophic cardiomyopathy, pharmacological treatmentAbstract
Introduction: Hypertrophic cardiomyopathy is a genetic disease characterized by left ventricular hypertrophy and, in some patients, left ventricular outflow tract obstruction. Mavacamten is a primary cardiac myosin inhibitor that reduces hypercontractility, decreases actin-myosin cross-bridge formation, and promotes more efficient diastolic and systolic function.
Objective: Synthesize the scientific evidence regarding the impact of mavacamten on the treatment of hypertrophic cardiomyopathy.
Methods: A comprehensive narrative literature review of recent publications identified in international scientific databases was conducted. Ten relevant publications were selected: five primary clinical studies and five complementary works focused on short- and medium-term efficacy, safety, and tolerability.
Results: Mavacamten demonstrated a significant reduction in the left ventricular outflow tract gradient, improvement in NYHA functional class, a decrease in cardiac stress biomarkers (NT-proBNP and troponin I), and favorable changes in cardiac structural remodeling.
Conclusions: Mavacamten constitutes an innovative and highly relevant pharmacological alternative, primarily for patients with symptomatic obstructive hypertrophic cardiomyopathy. Current evidence supports consistent clinical, symptomatic, and structural benefits, although future research with extended follow-up is needed to conclusively confirm its long-term efficacy and safety profile.
Downloads
References
Abdullah, M., Thalib, H. I., Tahir, M. B., Khalid, N., Mushtaq, A., Afzal, M. A., Moore, M. D., Sharma, N., Muddassir, S., Ayers, M. P., Albaghdadi, M., & Aronow, W. S. (2026). Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials. International Journal of Cardiology: Heart & Vasculature, 64, Article 101908. https://doi.org/10.1016/j.ijcha.2026.101908
Bello, J., & Pellegrini, M. V. (2026). Mavacamten. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK582152/
Bishev, D., Fabara, S., Loseke, I., Alok, A., Al-Ani, H., & Bazikian, Y. (2023). Efficacy and safety of mavacamten in the treatment of hypertrophic cardiomyopathy: A systematic review. Heart, Lung and Circulation, 32(9), 1049–1056. https://doi.org/10.1016/j.hlc.2023.05.019
Braunwald, E., Saberi, S., Abraham, T. P., Elliott, P. M., & Olivotto, I. (2023). Mavacamten: A first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. European Heart Journal, 44(44), 4622–4633. https://doi.org/10.1093/eurheartj/ehad637
Butzner, M., Leslie, D. L., Cuffee, Y., Hollenbeak, C. S., Sciamanna, C., & Abraham, T. (2022). Stable rates of obstructive hypertrophic cardiomyopathy in a contemporary era. Frontiers in Cardiovascular Medicine, 8, Article 765876. https://doi.org/10.3389/fcvm.2021.765876
Chu, E. L. W., Kim, D. S., & Masri, A. (2025). Emerging pharmacological and invasive therapies for hypertrophic cardiomyopathy with obstructive physiology. Cardiac Failure Review, 11, Article e27. https://doi.org/10.15420/cfr.2025.08
Gómez, L. E., Atamañuk, A. N., Jaimovich, G., & Bruque, C. D. (2025). Miocardiopatía hipertrófica: avances en diagnóstico y tratamiento. Medicina (Buenos Aires), 85(6), 1367–1383. https://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802025001001367
Keam, S. J. (2022). Mavacamten: First approval. Drugs, 82(10), 1127–1135. https://doi.org/10.1007/s40265-022-01739-7
Massera, D., Sherrid, M. V., Adlestein, E., Bokhari, N., Alvarez, I. C., Wu, W. Y., Reuter, M. C., Maron, M. S., Maron, B. J., & Rowin, E. J. (2025). Disopyramide revisited for treatment of symptomatic obstructive hypertrophic cardiomyopathy: Efficacy and safety in patients treated for at least 5 years. Journal of the American Heart Association, 14(2), Article e037639. https://doi.org/10.1161/JAHA.124.037639
Morgan, W., Barron, K., Hudson, O., Smith, C., Patel, N., Arora, P., & Arora, G. (2026). Long-term efficacy of mavacamten in reducing left ventricular mass in a multi-ethnic cohort with obstructive hypertrophic cardiomyopathy. The American Journal of Cardiology, 266, 67–69. https://doi.org/10.1016/j.amjcard.2026.02.015
Ramchand, J., & Bennett, R. G. (2026). Cardiac myosin inhibitors in hypertrophic cardiomyopathy: Current evidence and future perspectives. Current Cardiology Reports. Advance online publication. https://doi.org/10.1007/s11936-026-01142-5
Rossano, J. W., Canter, C., Wolf, C. M., Papez, A., Gambra, M., Bryant, R. M., Alejos, J., McCulloch, M., Sarquella Brugada, G., Bock, M. J., Jeewa, A., Pearce, F. B., Desai, M. Y., Favatella, N., Javidialsaadi, A., Phung, V., Rano, T., Zhu, L., Dyme, J. L., & Mital, S. (2026). Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy. New England Journal of Medicine, 395(4), 362–373. https://doi.org/10.1056/NEJMoa2601103
Sen-Martín, L., Fernández-Trasancos, Á., López-Unzu, M. Á., Bak, A., Zafra-Castellano, M., Srikantharajah, R., Pathak, D., Klotz, A., Kuehn, M. N., Ferrarini, A., Labrador-Cantarero, V., Sánchez-Ortiz, D., Pricolo, M. R., Vicente, N., Velázquez-Carreras, D., Sánchez-García, L., Sicilia, J., Nicolás-Ávila, J. Á., Sánchez-Díaz, M., . . . Alegre-Cebollada, J. (2026). Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy. Nature Cardiovascular Research, 5(7), 638–657. https://doi.org/10.1038/s44161-026-00833-3
Wan, L., Chen, X., Huang, Z., Ren, J., Lu, W., & Ran, H. (2026). Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work. Clinical Physiology and Functional Imaging, 46(4), Article e70084. https://doi.org/10.1111/cpf.70084
Wang, Y., Liu, X., Ma, L., Liu, Y., Cao, Y., An, G., Liu, F., & Dong, M. (2026). Obstructive hypertrophic cardiomyopathy with degenerative mitral regurgitation: A new treatment strategy using mavacamten combined with M-TEER. JACC: Case Reports, 31(15), Article 107398. https://doi.org/10.1016/j.jaccas.2026.107398
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Karen Jessica Pilatasig Bazurto, Millie Tiffani León Jiménez, Edison Humberto Ruiz Intriago, Evelyn Yuliana Lara Llanos, Andrés Roberto García Chavarria (Autor/a)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Los artículos publicados en la revista se distribuyen bajo la licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esta licencia permite a terceros descargar, copiar, distribuir, adaptar y reutilizar una obra, incluso con fines comerciales, siempre que se otorgue el crédito adecuado al autor original.
